Literature DB >> 17694380

Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.

E Chorianopoulos, D Jäger, H A Katus, N Frey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17694380     DOI： 10.1007/s00392-007-0567-z

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  4 in total

1.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Bruce G Redman; Gary R Hudes; George Wilding; Robert A Figlin; Michelle S Ginsberg; Sindy T Kim; Charles M Baum; Samuel E DePrimo; Jim Z Li; Carlo L Bello; Charles P Theuer; Daniel J George; Brian I Rini
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

2.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

Authors:  David R D'Adamo; Sibyl E Anderson; Karen Albritton; Jennifer Yamada; Elyn Riedel; Kelly Scheu; Gary K Schwartz; Helen Chen; Robert G Maki
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

3.  Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000.

Authors:  R Reibis; C Dovifat; R Dissmann; B Ehrlich; S Schulz; K Stolze; K Wegscheider; H Völler
Journal:  Clin Res Cardiol       Date:  2006-01-19       Impact factor: 5.460

4.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440
  4 in total
  2 in total

1.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

Review 2.  Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Authors:  Young Kwang Chae; Lauren Chiec; Scott K Adney; Josh Waitzman; Ricardo Costa; Benedito Carneiro; Maria Matsangou; Mark Agulnik; Peter Kopp; Frank Giles
Journal:  Oncotarget       Date:  2018-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.